로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LRRC15

LRRC15

요약

Name:Leucine-rich repeat-containing protein 15
Target Synonym:LRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Preclinical

제품 리스트 구매

일부의 생물활성 데이터

CHEK-ATP123-Cell-based assay
 LRRC15 FACS

Expression analysis of human LRRC15 on HEK293/Human LRRC15 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human LRRC15 Stable Cell Line or negative control cell using anti-human LRRC15 antibody followed by staining with FITC anti-mouse IgG antibody.

LR5-R82E3-ELISA
 LRRC15 ELISA

Immobilized Samrotamab at 5 μg/mL (100 μL/well) can bind Biotinylated Rat LRRC15 / LIB Protein, His,Avitag (MALS verified) (Cat. No. LR5-R82E3) with a linear range of 0.3-5 ng/mL (QC tested).

LR5-H51H3-MALS-HPLC
LRRC15 MALS images

The purity of Human LRRC15 Protein, His Tag (Cat. No. LR5-H51H3) is more than 90% and the molecular weight of this protein is around 55-85 kDa verified by SEC-MALS.

Synonym Name

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Samrotamab vedotin ABBV-085; PR-1498487-MMAE Abbvie Inc Details

This web search service is supported by Google Inc.

totop